A Comparative Study on Ivermectin-Doxycycline andHydroxychloroquine-Azithromycin Therapy on COVID-19 Patients

Abstract

Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combina tion therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mgBID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithro mycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symp tomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if theresult found positive. Time to the negative PCR and symptomatic recovery was measured for each group. Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at amean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of9.33 days and were symptoms-free at 6.99 days. In group A 31.67% of patients expressed symptoms caused by medica tion, this was 46.43% in group B. Conclusion: The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combina tion of Hydroxychloroquine-Azithromycin for mild to moderate COVID19 disease.